N
Google TrendSOCIAL SECURITY 2027 COLA ANNOUNCEMENT (500+) — Social Security's Trump Bump-Driven 2027 COLA Will Likely Feature a Grim Reality for Beneficiaries
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:social security 2027 cola announcement500+benfica vs vitória sc200+energy ceasefire200+elliot anderson200+r.c.d. mallorca - u. d. las palmas200+quinyon mitchell2000+tornado north carolina1000+sean young500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Advanced Triple-Negative" (30 stories)

Top Headline Story

Datopotamab Deruxtecan Approved in China for Advanced Triple-Negative Breast Cancer
Lead StoryOncodailyworld
2d ago

Datopotamab Deruxtecan Approved in China for Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBKa3k2Tm9veUk2SG9maEI1R0d5U3huX1RpVUFLQjdBd3JJVnBKWHNsUmZKdERNQ1ppRHczaUIyNnZLOEVxNGpJUHh3Wjhfd241Mng4c0Raa0habzh0UFlXZVdBbEhfS3pzZE9MeEYxV0p1WGQzcmc?oc=5" target="_blank">Datopotamab Deruxtecan Approved in China for Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+16m ago

social security 2027 cola announcement

Social Security's Trump Bump-Driven 2027 COLA Will Likely Feature a Grim Reality for Beneficiaries

Filter stories
200+26m ago

benfica vs vitória sc

Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável

Filter stories
200+26m ago

energy ceasefire

Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’

Filter stories
200+26m ago

elliot anderson

James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton

Filter stories

Search Results for "Advanced Triple-Negative"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape
ASCO Publicationsgeneral

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTFA3R3FLdkQ0cUVkRzNadkNkUEJHNkdOTDl0UGVkVGJfNHRSRFh0a0c0dlZJNkF1VVhOV291cjBfX2FwTlBmMXlHaTFnZ2hrUlg5OFFTcG41RWlfcVE?oc=5" target="_blank">Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape</a>  <font color="#6f6f6f">ASCO Publications</font>

Read Full StoryMore like this
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
PR Newswiregeneral

Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxPdlFwQm1SZDBzYVFuekZsM0JjcHdadFY1NGpTemZ6dzdwbElnRjJ1d1FWMkZHTmY1TnFFOGgydnkwb3dCWl8zQUdUeUgxYzFjcGg3U2NrRUswVU5INUkxbW9vbzI2a3VKb0xURzloZXIxV0dvOVM5dWRsLTFFTGwyTURoOUtSeHp3ejUwbFYzNklSbHJHNmJGTEFHQzl0VU1JZWRZMGVMS3F5bFdhLXZWenA2S3ZpOXI4elZQTVZmTUxPR1ZkTElGVEtIclNGb1lJTmdfWXFqeF9JTHprWjczWm9jdDlFMEZDdmNxZWxocEtieml0dU81eHRDLUxubVdlVVU5UWdVWUxDbnRGRjRyUA?oc=5" target="_blank">Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
Naturegeneral

Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HNGU0cW9qRDFQV3FlMVFlWC10bFRSaXFEN05uUk5wXzYwaXFQQzhUN0NVcEZxSFVLMDNreWxhVjhBTzE0WnRTZUdrRWhDeWVER0ZpM2RjbW96QzJ5RVRN?oc=5" target="_blank">Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Datopotamab Deruxtecan Improves Survival Outcomes in Advanced Triple-Negative Breast Cancer
Oncology Nursing Newsgeneral

Datopotamab Deruxtecan Improves Survival Outcomes in Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOX3hBZHkyY044bTBNQjJNRHRfbWkyYV82YUVQLWlxT0hoRnVIWW5PSEtLa3UwRGdybkN6NnU5ZjA4dzdTY2RDUVJPSVpHUHVSRE1EVkd6cWdCRzBrNmZ2TmpuU1NRNlpSbEQzNXZmeW1SaHJOdVh4QlAzQlg3TmdvWGxuMW80MTM4cDllRnRsM1dYZFBOel82aWwtSVB4MHVlVlpCNkJYelVtOUpkcUd2NVdPZFo5NzRDUmRLSTNkVnJmWUJQd1E?oc=5" target="_blank">Datopotamab Deruxtecan Improves Survival Outcomes in Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Datroway Improves Survival in Advanced Triple-Negative Breast Cancer Trial
Cure Todaygeneral

Datroway Improves Survival in Advanced Triple-Negative Breast Cancer Trial

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNYmJGMklIWV9FQjdsT0xLb1RlYllSTUFIYUtacXBtbVhJVW5fRTNBLUhTVTVzUjk2djREbVNQQTdXYmpvTjI1RU9wcjg1Tm9CUFJyVlRybzhmTDcwUVV0M0VfR1JpYzk2T1pSemZJbWNPZnc0R0t4QnNnbUxfMUdTMDZwS1NXQkdQX1FBay1rcHZwbmZNblhvaGNMa1l1RXZxa0FWYy1VRms?oc=5" target="_blank">Datroway Improves Survival in Advanced Triple-Negative Breast Cancer Trial</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
NEJMgeneral

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1KNWFLYjZXdTBPT1BqTnlSSDZjUmFjbElRT2U1MDVNM21OcjFOellkZXJkamY5RHNIcEpES3hlT0hxekx3LWJ6cWt4RjBiaU9sN1BHdXFHVExWb2hLUzhF?oc=5" target="_blank">Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer
Pharmacy Timesgeneral

FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOd0VwcFFyM2VoUjFnQ1RsU0NLYzFxYjFuT3cxeTdsZlJxbjBBbGFESVgwd2hRc3FlRVZxWWNPUXlmOWp4MlZLaUtfVnFGN1ZyWkNTOC1WYWdGWmFvcE9qWnJtbVJvY0NuYjlsSTFNWmd3clEyMTBRX2lzdUdaOHAxTkFIVjVRb3hTZUtoSGk3V3RxSGVDOURfYWdqV2tsVWN0WU9pQ1JZMlhxcmNxRkdEWDVVU250bzZTNEdzY1ljQkRzdlEycG9DekliN0NSWkQyNGc?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2 in TNBC
Oncology News Centralgeneral

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2 in TNBC

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNNC1nMlREdzdVRF84WTJURFR1TFBIVTlWdlFVSEdGOERNTFJCOUZIRU1rZjlQZlhFajJCRUNneFkyNmNRalZkd19kekNpM3JDS05uMlZDaTk5SFM4ZkVGYXQ4TmlKdkw4SlN6anF6eHlEa0k4cENmMFJhdW10OWNtdmtQdTI4cERMQjF3b3R1VU9uVzMydXNCZG54VHNhdU81eG5DRWgzbjJ3SjFRMEpGLVA1Z1VfUDdJTWZHZE83cVdaYldfbmc?oc=5" target="_blank">Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2 in TNBC</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer
Wiley & Sonsgeneral

TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE10RVBFNUFScTY0T0sxNXZZci04ajVGYURFemU0QURNMnE1WUxWaFNCN2xUc25Pck9vcmczenZUUUYwTmVMeTVRMGVwNWdVV2h0cDZRUlpZeFFLMXRRLWFwRUlOSl9pRy1uMlBFYXI1Yko5TEx2UVdwVEJ2VQ?oc=5" target="_blank">TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer</a>  <font color="#6f6f6f">Wiley & Sons</font>

Read Full StoryMore like this
130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYN
CancerNetworkworld

130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYN

<a href="https://news.google.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?oc=5" target="_blank">130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYN</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer
2 Minute Medicinegeneral

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPeHYzdUIxcFRMVmZKTFM2cW8wcnYyZjY3bUlUOVM1S3o4Y2xJcmI5NWVoeWZ0UFpKU19wZkdRRnozVExRUzlGajdQTHIySU9oUFNkMS02QjV5ZUthVmJXNGY2aXJXLVNiYlpyZ19BQ05meVJxRTZjbTRQZ2tZZXo5SGN5RFJUbzZXN3NhRmFXS3B3WDQyTFpDTnRuWVBUT0pleWtjYWxVU1BvbUgtUFItd2w0T2g1VUs1Ymo4QkQ2X2Njb0xfWExEVFgtN2s3UQ?oc=5" target="_blank">Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer</a>  <font color="#6f6f6f">2 Minute Medicine</font>

Read Full StoryMore like this
FDA Approves New Treatment for Triple-Negative Breast Cancer
Memorial Sloan Kettering Cancer Centergeneral

FDA Approves New Treatment for Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPSjdwR3p2T2kwd3JlX1V0elo5R1VVREIzcXJpZEJud2toS3M1eGwtV1NjaTMzc0RKaHBrRmdDOW12YS1xLUxOSjU3RkRSR3VNZVF3RXB2dE5pYTI2T2ZxM2dGT2MtZERlLXktMllDSGNBRVB1ZlkzWWhXZEIwc3JseEdFVDhjZmc?oc=5" target="_blank">FDA Approves New Treatment for Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Memorial Sloan Kettering Cancer Center</font>

Read Full StoryMore like this
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZenecageneral

Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPWEpYdWUtelUxSkhNVTdFaDZKdUxlRUt4OXVlTnZNNFNHODFqMmxWbkZWcHpBVzhuU3ViUFEySHJaa29SMnRzeThZdDA1LXhVLW13OXhORU05R2cyaE5wbFZxbkF6NmQ0RWdzcmx0SWRyQnpuMGtfWjRtR29ZM3l3dTUyZDgyQ2VpQk5uZExpUkFZdmd3blR1YWlfblg2OFhnTVhZU0dfR0VuMGpaeGlJUGVxR0VnUQ?oc=5" target="_blank">Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates</a>  <font color="#6f6f6f">AstraZeneca</font>

Read Full StoryMore like this
Antibody-drug Conjugate Approved for Certain Patients With Advanced Triple-negative Breast Cancer
American Association for Cancer Researchtech

Antibody-drug Conjugate Approved for Certain Patients With Advanced Triple-negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNaEhBQjRLbmtoRUtqXzlkRjl5Sjc0Q3ZUbXFSTDczbFlTd09KdVNNR08zVlJoZGF4VmNVOVVwdndwV1k4TDJGZi1wY1lDQWVmVFhmWjhpU19CdXcyZ19FQXFtT0kwM1R3dlZOaGVHYk9rVDllbE0wNE9GMkJkSEJDNGMwSzdic3F1emxUQWNqVWd6WnFfdktTenZoWnFXNWQwSUtLVXY3Tmo1UVlPbHF2LW9pQU1qbThCalVOTXpVdVRfX2QzaUlmaGFaM3hxeUZUaEVvWFp5TERnMUJZS0UzcksxcXdRWVo2QU45YTNYMXpYa0dFY1E?oc=5" target="_blank">Antibody-drug Conjugate Approved for Certain Patients With Advanced Triple-negative Breast Cancer</a>  <font color="#6f6f6f">American Association for Cancer Research</font>

Read Full StoryMore like this
FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer
Oncology Nursing Newsgeneral

FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNZURwNjIza2J5aENMbDhhSEhLWDZHd2RDWTdGclJpX3NtcjJwa2p6Y1BtTWNJRXVnVlpBNWRBdGxISXFMZnZJeFNTOE1tQUZJdWtub2R0bFU4UDJJRjc5WTFvdnJlMW1RMzRFaUprSWZST1lQSUwxaDFLN2o5V1FNTTJMQndGbG85N2hlQUpVRXpUaTN3Wi1ReXRzUGFXSkhIUkZDRjk0NFpqbnhabktsRFpMb3JJbEVKSkR1Mw?oc=5" target="_blank">FDA Approves Sacituzumab Govitecan-hziy for First-Line Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
Cure Todaygeneral

FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPaV9nYnRJOGVqVXVhUGYyWHJHazRYZjBTNXRQVkJMdHJLaHVsU0VtQzFNY2xoRWZzMjBiSzltWDJtLUo4bFRvTUQ5MGZORFQ4ZnliYmNZQTRucXJ2WHhQVTQ5ZVBEd0RBMExjV1RYRE1Ca0MtSTVMeHpIQ1UtcUFrODhTSXhWam9IeWpzbkM3OE1IUFdGWTA5Vzl4dlh3Um5wMFJPX1Rjd3F5Q3FCLUd5Z2NYdXpPUQ?oc=5" target="_blank">FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Izalontamab Brengitecan Improves Survival in Triple-Negative Breast Cancer
Oncology News Centralgeneral

Izalontamab Brengitecan Improves Survival in Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQRDVoT1Y4NHAxQy0xZVFfaWg2V0V2SXFpYloxcnp4aUdQMXRPMUcwdmM4UDhZdEd4S0pxQlBTMEhGWWotMVdvdnlTQUZ3OGRsVGJtNHJCV0h0QnNoYjRQak1MY3ZmX1M5eFdyT2RFdjVaZ1ZFVWVVcTZnWUhyaUxZTzR3Nng3VFdIRG9xLVhBQzJZQ3kxb3FqcjdvOTV3blFMZGtwLUQ4TkktVDQwcEFxcWloMVQ2OGVjVmtZWVU0RGowbmFUZHlLU1dIdG0yT01zTEkwTDdnM2JnNGxSTy1ULWhFQQ?oc=5" target="_blank">Izalontamab Brengitecan Improves Survival in Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial
Naturegeneral

Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9VU1RFTW1CdEMzODZ2WHhzTEJoSHVDLU02TlByY2E4d2lZTlRyQVZLOUVGSlRGYkdFUlY1SGZjTWlzWGNpVTFnTWhiZWc5UWRVb2pUaERIYzYtRjZqelpr?oc=5" target="_blank">Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)
CancerNetworkworld

131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)

<a href="https://news.google.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?oc=5" target="_blank">131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
The ASCO Postgeneral

Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQRnB6UFBlOU1jVmNvQktFTDVVYUctY0p0Qmt0QlpBVHY0dWNsd1JYOGZUTURQUWhVMnpleWx0Tk0xX2N1dWF1N0RTTzRZbHdkVGViSVRkQ3l6MHd5aHpZdlRobmJsVUdud0doaXpPMFR6cVN3T2dqMjBodWh3eHRzRV9xYzQxNFd4YkNPaVFjVUhmQ3E2NFBkYWJZNTBSdHl0T2dENEZpNXpCdldvS1BOS0MwWlNIQ0F1N2l1b1hTNlFYN2NkS2VWLThGUU5IMzBKZEp3TXgtRmZ5cnpXcldtdHFxWQ?oc=5" target="_blank">Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
CancerNetworkgeneral

Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPWmJIMlljU2F0WTZ4ZFc0MUpwbUVMRnFfS3FzRXg0c0ZqUDdUMFQ4Vkg0bzFNQjZaTldYUWl6MnBIbnNFXzZFblF3N2NtNTUwVU9jYzRKclBxbmxGano0U0htczUzdXlSNERVbFFCUmk2T1dPaXd1dndTR3ctbXhhcmlScnBVbTVIcEU1ak5ycnZKVlhFS1FFRGstT3REZzJpTGJXQ3VObw?oc=5" target="_blank">Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Antibody-Drug Conjugate Provides Better Results for Triple-Negative Breast Cancer
Cancer Healthgeneral

Antibody-Drug Conjugate Provides Better Results for Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNZXc1ZmxFWXFKV3ljTm9qM1o4UTRISEFHU3RNWmNFYTQ4WS04LW9uTDgzcEdoTm9aUFBJb01PRXhINlhIdVdKMnNrVElyeGl5c0xwVmN3STZvbXpiT3lpOWViNUZHRDVnLTZWTUQ0dEstTjNhV1NCcmZPeTg1cFYxY2lubG1iVUhMRzBVbFFKVUoxWjZBMXBlUF9mTl9ud3FhSC1BTFdHRUprYUg4a0lhdFVyVnZFbTNCU29sMnU0V3hBUVFUcVM5NlVvejNCZXdIVHVKcUlxWTFrd3JSRFE?oc=5" target="_blank">Antibody-Drug Conjugate Provides Better Results for Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Cancer Health</font>

Read Full StoryMore like this
FDA Grants Fast Track Designation to RPTR-1.201 for Advanced TNBC
Targeted Oncologygeneral

FDA Grants Fast Track Designation to RPTR-1.201 for Advanced TNBC

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPZ3U4T0owYlIwN2VERHhiOU94MDBRNWpsMUV3T1pRcDdiekdiNEp0TlV4a3RKY21LRVRpZ1RSRDhXWFFadkFYVWNPdkZsMlZyVG44M3R0NlM5WDF0ektZSmpBclBFMzRrdC0tdDd2OTJUUElNdGFqMWNRN2d5TTVRWkgtRXczSHVrenFZaVRsbTRqWjJZaXlNUUdKYU1aS3M?oc=5" target="_blank">FDA Grants Fast Track Designation to RPTR-1.201 for Advanced TNBC</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Datroway: FDA Approves Antibody-Drug Conjugate Injection for Advanced Triple-Negative Breast Cancer
WebMDgeneral

Datroway: FDA Approves Antibody-Drug Conjugate Injection for Advanced Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPZmxWUlRyeVVaRHJxQ1RJUXhCTHlFdWNocm1jVk43dGFXeHo2NWtaenBub0xiVEEzLXhFVHprVExDZDZsd2lXUGNIZmVsSEJxeGxIYmttTWl1OWdUdDNfZzF6WF9UZ1pMUTNaVWJ1Y0pYVlNCamdNYTAySzBFbnRrTEVVdmN1aHM?oc=5" target="_blank">Datroway: FDA Approves Antibody-Drug Conjugate Injection for Advanced Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">WebMD</font>

Read Full StoryMore like this
Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC
CancerNetworkgeneral

Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNVWE5cldWV0pxbEdkaGlPOTN6RnNkbHVPNXFldldyRkNzcGFTZzZMamdKYS1EVlJON0ZBTXZjWjhsdDc4VC02RkpLeDFlM1BOaUQtaWZQd3JBekFWby1JeUN5WTc2cGlsQ0otUmczUmhHdTdCREZqLVRWQXk0SUJndFVlOHlUclR6emVqZzZRSl9TdVhXREoxS2pmRVM?oc=5" target="_blank">Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Additional TROPION-Breast02 Analyses Support Dato-DXd as First-Line Option in Advanced TNBC
DocWireNewsgeneral

Additional TROPION-Breast02 Analyses Support Dato-DXd as First-Line Option in Advanced TNBC

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOOENHVHlaU3NvSGJGcHhXcGFiMUdlZXNfWmlGLXhqMWpLaXRkMUQ2VV9TaEl1LWMzS0p2WFBfQXN1MXlRaW93cFJ6V1Nub0FuMThTM1FfbFBNdjRnVnJlVGZ3Tl9iWkNqVDNZckR3OGMwX0xtSHJ0NUZBZzRDYm1ZcGZlbFpnRllISGVTNXNuZV95eE1xbi1PYU51ZTMwQWRVV0Focnc4ZmZ0VTBUc2dkd2ZjYTF6MWxzOXhkYlBMUUZUQQ?oc=5" target="_blank">Additional TROPION-Breast02 Analyses Support Dato-DXd as First-Line Option in Advanced TNBC</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
Pharmaceutical Executivegeneral

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNSTdQMlFETGlFa1RCQ292MVFIR2V4eVNQS2tld1d0ZlJjSHNNYXdnZDRoNlRtNzJqNjF3cjRlcmdkSjFwdF9Oa1RJclJuSXhfMU9DbTNkRlg2dDNRSmU0Ylp2anBMZVV2VGdYTk1aYnpBZUFYWDEwQ2tnT3A5WlFnTEpQLTlJcFhPay1seFcyUDd2RGs1RE41dWo3Y2k2SWRkSmx3SkFhcGNrNDNi?oc=5" target="_blank">FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study
CancerNetworkworld

80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study

<a href="https://news.google.com/rss/articles/CBMi1gJBVV95cUxNMVZfWEd6a1R5SWcwTTJxbnhNNkFvY052bER0SmF6RlQxYUdEdFB0blFYVm0zYkVrUVNsb1h0SzVERUV6TXFxWm5CV3dQVU1YZ0JwOWdMOXUtMlVBWjdCTThpWnkzUjVrdGJDaTJhMk84RjJpdWY3Yi02YVhqUF9fZHBVWXhXbEtVQXl3ZWViTWlaZDVZTjVlcjM3ZVExRWpheFZyNzB2TlJXMWNLZkVGLWppTWNXS0ZBZWtRMDVwT3g0cTdTdTcyS0JBRW9VajExUU5rZEJ3bEJIMkx2VjM5NTdPNFVvdkt0VDhyeDRiQ1JoRjFLSDBVX2lHOVZaTWVzWHY1cWE5WjBjSnJZYjVQc3pmeGphVXJtdmQ1dFdhMzBqa0MtRkhoZVA1eHhId2t1eDJlejBSc1FtdExDRVFWUUl5dmpYcXlLVjBGU19rdU9XSVBNM2c?oc=5" target="_blank">80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
CancerNetworkgeneral

NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPS01NUEY4ekprb01xOHVJNXJrbkFCZWEzalBHcG9ZQXplcllHc1hnSElyM1hJc2dqUVpzWTFxV2hhMXV5Z2lpcnBab1Vic2NNcnI3aTJSUFBTVmMwMXhNdm5iNE1YREktWjBhdTA0al9NZ1F0UXZyQnlCeks0U2FPeE1CR0NzZ0dyaG1EX0JOSUxOd2VHVUlnRHpqbmVjRGQtQWZlaEk2Y0FRZw?oc=5" target="_blank">NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"Advanced Triple-Negative" — Live Google News Trends & Headlines